Feb 18, 2026 09:05AM
Feb 18, 2026 09:05AM
Feb 9, 2026 09:20AM
Feb 9, 2026 09:20AM
Jan 21, 2026 08:30AM
Jan 21, 2026 08:30AM
Jan 8, 2026 08:45AM World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Dec 22, 2025 09:18AM
Dec 22, 2025 09:17AM
Dec 4, 2025 07:30AM
Nov 24, 2025 09:56AM
Nov 24, 2025 09:56AM
Oct 6, 2025 09:00AM
Sep 10, 2025 02:30PM NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Sep 4, 2025 08:49AM
Sep 4, 2025 08:49AM
Aug 1, 2025 09:00AM
Jul 22, 2025 08:42AM
Apr 24, 2025 09:09AM
Apr 24, 2025 09:09AM
Apr 9, 2025 08:30AM Neurosense Therapeutics (NRSN) Announces Transformative Phase 2b MicroRNA Data
Apr 9, 2025 08:30AM
Apr 7, 2025 05:14PM
Apr 4, 2025 09:10AM
Mar 20, 2025 10:30AM
Mar 17, 2025 08:30AM
Jan 6, 2025 09:02AM
Jan 6, 2025 09:00AM NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
Dec 23, 2024 09:00AM
Dec 18, 2024 10:25AM
Dec 11, 2024 09:25AM
Dec 11, 2024 09:25AM
Dec 4, 2024 08:30AM
Dec 2, 2024 08:32AM
Dec 2, 2024 08:30AM NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
Nov 21, 2024 09:20AM
Oct 28, 2024 08:30AM
Oct 28, 2024 08:30AM
Oct 24, 2024 08:30AM
Oct 15, 2024 09:16AM
Oct 15, 2024 09:15AM
Oct 9, 2024 09:02AM Neurosense Therapeutics (NRSN) to File for Early Commercialization of ALS Treatment in Canada
Oct 9, 2024 09:00AM
Oct 7, 2024 09:00AM
Sep 24, 2024 09:05AM
Sep 24, 2024 09:05AM
Sep 24, 2024 09:00AM
Sep 24, 2024 09:00AM
Aug 30, 2024 04:30PM Neurosense Therapeutics (NRSN) Receives Nasdaq Non-compliance Notice
Aug 30, 2024 04:30PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All